The left’s racism has now infiltrated the healthcare system.
Guidance issued by the Biden administration is now allowing “race or ethnicity” to play a part in who gets drugs first.
Guidance issued by the Biden administration states certain individuals may be considered “high risk” and more quickly qualify for monoclonal antibodies and oral antivirals used to treat COVID-19 based on their “race or ethnicity.”
In a fact sheet issued for healthcare providers by the Food and Drug Administration, the federal agency approved emergency use authorizations of sotrovimab â€“ a monoclonal antibody proven to be effective against the Omicron variant â€“ only to patients considered “high risk.”
The guidance, updated in December 2021, says “medical conditions or factors” such as “race or ethnicity” have the potential to “place individual patients at high risk for progression to severe COVID-19,” adding that the “authorization of sotrovimab under the EUA is not limited to” other factors outlined by the agency.
Older age, obesity, pregnancy, chronic kidney disease, diabetes, and cardiovascular disease are among the multiple medical conditions and factors associated with what are considered “high risk” individuals by the FDA.
Some states, including New York and Utah, have made it clear they will prioritize certain racial minorities over other high–risk patients when it comes to the distribution of particular COVID treatments.
The Palmieri Report is a Pro-America News Outlet founded by Jacob Palmieri. The Palmieri Report is dedicated to giving people the truth so that they can form their own informed political opinions.Â
Follow us on social media:
Listen to our Daily News Podcast!